Pinane-thromboxane A2 (PTA2, [1alpha,2 beta(Z),-3 alpha (1E,3R*),5 alpha]-7-(3-(3-hydroxy-1-octenyl)-6,6-dimethylbicyclo[3.1.1]hept-2-yl)-5-heptenoi c acid) has been synthesized and tested for biological activity in systems responsive to thromboxane A2, stable prostaglandin endoperoxide (PGH2) analogs, and prostatacyclin (PGI2). At low concentrations, PTA2 inhibited cat coronary artery constriction induced by stable prostaglandin endoperoxide analogs, and it stabilized liver lysosomes. At slightly higher concentrations, it inhibited platelet aggregation. At still higher concentrations, PTA2 inhibited thromboxane synthetase, but it had no effect on prostacyclin synthetase. The analog also had no effect on the inhibition of platelet aggregation by PGI2 or prostaglandin D2. It is suggested that PTA2 has a suitable biochemical profile for use as an antithrombotic agent.

中文翻译：

---

ane烷-血栓烷A2（一种冠状动脉收缩，血小板聚集和血栓烷形成的选择性抑制剂）的合成和生物学特性。

ane烷-血栓烷A2（PTA2，[1alpha，2 beta（Z），-3 alpha（1E，3R *），5 alpha] -7-（3-（3-羟基-1-辛烯基）-6,6-二甲基双环[3.1.1]庚-2-基）-5-庚烯酸已合成并在对血栓烷A2，稳定的前列腺素内过氧化物（PGH2）类似物和前列腺素（PGI2）敏感的系统中进行了生物学活性测试。在低浓度下，PTA2抑制稳定的前列腺素内过氧化物类似物诱导的猫冠状动脉收缩，并稳定肝脏溶酶体。在稍高的浓度下，它抑制血小板聚集。在更高的浓度下，PTA2抑制血栓烷合成酶，但对前列环素合成酶没有影响。该类似物也对PGI2或前列腺素D2对血小板聚集的抑制没有作用。